Heterogeneity in Tumors and Resistance to EGFR TKI Therapy-Letter

Cancer Res. 2016 May 15;76(10):3109-10. doi: 10.1158/0008-5472.CAN-15-2916. Epub 2016 May 2.

Authors

Kenichi Suda¹, Christopher J Rivard², Tetsuya Mitsudomi³, Fred R Hirsch²

Affiliations

¹ Division of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, Colorado. Division of Thoracic Surgery, Department of Surgery, Kinki University Faculty of Medicine, Osaka-Sayama, Japan. kenichi.suda@ucdenver.edu.
² Division of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, Colorado.
³ Division of Thoracic Surgery, Department of Surgery, Kinki University Faculty of Medicine, Osaka-Sayama, Japan.

No abstract available

Publication types

Letter
Comment

MeSH terms

Carcinoma, Non-Small-Cell Lung*
Drug Resistance, Neoplasm
ErbB Receptors / genetics*
Humans
Lung Neoplasms
Mutation
Protein Kinase Inhibitors

Substances

Protein Kinase Inhibitors
ErbB Receptors

Grants and funding

P50 CA058187/CA/NCI NIH HHS/United States